News

According to the company, AVD-104 is an engineered glycan (sialic acid) nanoparticle designed to target the self-pattern recognition receptors on overly activated retinal immune cells, specifically macrophages and microglia.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

The researchers pointed out the eye can be a challenge to sample in living patients as, much like the brain, it is non-regenerative and obtaining a tissue biopsy would cause irreparable damage.

The company continues to turn to experts and leaders to support their mission and the development of new products through these appointments.

This gene therapy is designed to be a one-time intravitreally therapy that has demonstrated potent efficacy and a favorable safety profile in preclinical studies.

The American Academy of Ophthalmology (AAO) 2023 annual meeting is returning home to San Francisco on Friday November 3 through Monday November 6.

This study will evaluate a potential gene therapy treatment in which a targeted gene directly to the retina.

The company made this decision after completing phase 2 trials of the drug.

In the data shared, switching to SB15 from AFL maintained comparable clinical efficacy and safety in treating patients with neovascular age-related macular degeneration (nAMD), confirming biosimilarity between these agents before and after switching.

This effort will advance screening technology at Canada’s foremost specialist care provider in diabetes and endocrinology.

Eclipsing 100,000 doses sold to retinal specialists within the first full year after commercial launch is an important milestone for the company.

In the wake of the October 7 surprise attack by Hamas, Israel finds itself thrust into war, and ophthalmologists are working to provide the best care they can under the conditions they find themselves in.

Phase 2/3 SIGLEC trial are underway. Data shared at EURETINA 2023 shows continued safety with no drug-related adverse events thus far in cohorts 1, 2, 3, and 4.

Nathan Steinle, MD, spoke with Modern Retina's editor to give insights into his Retina Society presentation titled, "Phase 3 studies of dual inhibition of VEGF C/D and VEGF A using OPT-302 in combination With ranibizumab (ShORe Trial) or aflibercept (COAST Trial) in neovascular AMD."

At the 56th annual Retina Society congress in New York, David Boyer, MD, gave a presentation titled, "Subgroup analyses of phase 1 DAVIO Trial of EYP-1901 demonstrating reduced treatment burden in wet age-related macular degeneration."

Sophie Bakri, MD, MBA, shared insights from her presentation, "Comparison of the Antiangiogenic Profile of Tyrosine Kinase Inhibitors Vorolanib, Axitinib, and Sunitinib."

Researchers note their work reports a novel candidate gene for FEVR, which expands the spectrum of EMC1 variants and EMC1-related phenotypes, providing evidence for the prenatal diagnosis of candidate disease-causing EMC1 variants in FEVR.

The patent covers the company’s development of this cell transplant therapy as a treatment for geographic atrophy.

The use of silicone-free syringes advised with these drops.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

The investigators performed clinical examinations and obtained fundus photographs and inferior optical coherence tomography (OCT) images for both treatments at baseline and on days 1, 3, 8, 15, and 56 after the injections.

A modified endolaser setup was found to be safe and efficient for use during chandelier scleral buckling.

Researchers at the Warsaw, Poland-based International Center for Translational Eye Research decided to change that by introducing a new imaging method derived from optical coherence tomography. This led to the creation of even more advanced spatio-temporal optical coherence tomography.

Michael Engelbert, MD, PhD, discusses how personalized faricimab dosing shows promise in extending dosing intervals for patients with wet age-related macular degeneration, which can enhance long-term treatment outcomes and patient adherence.

A groundbreaking study conducted by the International Agency for the Prevention of Blindness (IAPB) and Kevin Frick, PhD, from Johns Hopkins University reveals that prioritizing better eye health could inject a staggering $50.4 billion annually into the US economy.

Comments for the draft should be submitted by December 13, 2023.

The meeting, being held from October 11-14 in New York City, will feature 4 presentations from ophthalmologists of the New York Eye and Ear Infirmary of Mount Sinai.

Visual acuity changes and conversion to neovascular AMD determined over 3 years in large patient cohort.

According to Roche, faricimab (Vabysmo)showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies.

New data, insights on clinical trials, and perspective from researchers will be among the information shared at the 56th annual Retina Society congress being held in New York.